Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial [PDF]
, 2020 Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the ...
Dauvilliers, Yves +4 more
core +4 more sources
Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP A Randomized Trial [PDF]
, 2021 BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION:
Dauvilliers, Yves +5 more
core +1 more source
Pharmacology Research & Perspectives, 2021 Several therapeutic options are currently available to treat excessive daytime sleepiness (EDS) in patients suffering from narcolepsy or obstructive sleep apnea.
Stéphane Krief +11 more
doaj +1 more source
European guideline and expert statements on the management of narcolepsy in adults and children [PDF]
, 2021 Background and purpose: Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment. This paper aims to provide evidence-based guidelines for the management of narcolepsy in both adults and ...
Baldin, Elisa +17 more
core +11 more sources
Sleep, 2021 Abstract Introduction Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor, is approved (US and EU) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnea (OSA) (37.5–150 mg/day).
Michael Thorpy +6 more
openaire +1 more source
Enantioseparation of solriamfetol and its major impurity phenylalaninol by capillary electrophoresis using sulfated gamma cyclodextrin [PDF]
, 2021 R-solriamfetol is a recently approved drug used for the treatment of excessive sleepiness associated with narcolepsy and sleep apnea. Herein, a capillary electrophoretic method was developed, enabling the simultaneous analysis of the API and its S ...
Béni, Szabolcs +6 more
core +3 more sources
Autonomic Dysfunction in Hypersomnia [PDF]
, 2023 Purpose of Review: This article provides a comprehensive overview of the literature on autonomic dysfunctions in centraldisorders of hypersomnolence: narcolepsy type 1 and type 2, idiopathic hypersomnia, and the Kleine-Levin syndrome.
Alessandro Silvani +4 more
core +1 more source
New Trends in the Quality Control of Enantiomeric Drugs: Quality by Design-Compliant Development of Chiral Capillary Electrophoresis Methods [PDF]
, 2022 Capillary electrophoresis (CE) is a potent method for analyzing chiral substances and is commonly used in the enantioseparation and chiral purity control of pharmaceuticals from different matrices.
Furlanetto S. +6 more
core +1 more source
Solriamfetol for the Use of Narcolepsy: A Systematic Review
Cureus, 2022 Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to ...
Iturburu, Alisson +9 more
openaire +2 more sources
The orexin story and orexin receptor antagonists for the treatment of insomnia
Journal of Sleep Research, Volume 32, Issue 6, December 2023., 2023 Summary Insomnia is present in up to one third of the adult population worldwide, and it can present independently or with other medical conditions such as mental, metabolic, or cardiovascular diseases, which highlights the importance of treating this multifaceted disorder.
Clemens Muehlan +3 more
wiley +1 more source